Abstract
We performed a phase I trial of CI-937 (DUP937), an anthrapyrazole, with the following objectives: (a) to determine the maximally tolerated dose in humans; (b) to define the toxicity spectrum of this agent; (c) to describe the pharmacokinetics of the drug; to test a pharmacokinetics based hypothesis of dose escalation; and (<â€to¢)relate drug pharmacoki netics to pharmacodynamics. CI-937 was administered as a single bolus injection every 3-4 weeks at doses ranging from 3.6 to 25.2 mg/m2. Thirty-two patients and 57 courses were Ã
Original language | English (US) |
---|---|
Pages (from-to) | 6317-6322 |
Number of pages | 6 |
Journal | Cancer research |
Volume | 51 |
State | Published - Dec 1991 |
ASJC Scopus subject areas
- Oncology
- Cancer Research